Cagrilintide – 10 mg

Cagrilintide is a long-acting analogue of the pancreatic hormone amylin. Amylin is naturally co-secreted with insulin and is involved in physiological processes associated with appetite regulation, glucose homeostasis, and gastric emptying. Cagrilintide has been developed as a longer-acting research compound for investigating amylin receptor-mediated signaling. The 10 mg presentation is intended for qualified research environments conducting controlled investigations into amylin biology, receptor pharmacology, metabolic signaling, peptide interactions, and related preclinical research models.

Key Features

10 mg research-grade cagrilintide Long-acting amylin analogue Relevant to amylin receptor research Suitable for metabolic and endocrine signaling studies Appropriate for peptide pharmacology research Intended for controlled in-vitro and preclinical research Suitable for analytical characterization and laboratory workflows Batch-level analytical documentation may be provided for applicable lots Research Focus Cagrilintide is being investigated for its activity within the amylin signaling pathway. Research programs have examined cagrilintide as a standalone amylin analogue as well as in combination with semaglutide, including the investigational CagriSema programme. Its long-acting profile and interaction with amylin-related pathways make cagrilintide a relevant compound for research into metabolic signaling, receptor pharmacology, appetite-related pathways, and peptide biology.

Important Notice

This product is supplied strictly for research and laboratory use. Cagrilintide remains an investigational compound and should not be represented as an approved pharmaceutical product. It is not intended for human or veterinary use, self-administration, consumption, diagnosis, treatment, or prevention of disease. This research material should be handled only by appropriately qualified personnel in accordance with applicable laboratory protocols and regulations.